Sanford S. Zweifach
Independent DirectorMr. Sanford S. Zweifach, also known as Sandy, is Chairman of the Board of Codebreaker Tx, Inc. Mr. Zweifach serves as an Operating Advisor at Symbiosis Capital Partners, LLC. He is Partner & Advisor of Bioqube Ventures NV from August 2024. Mr. Sanford S. Zweifach, also known as Sandy, is an Independent Chairman at Carisma Therapeutics, Inc. since March 7, 2023. He served as Chairman of the Board at CARISMA Therapeutics Inc. since November 2021 and its Director since November 2021. He has been Independent Director of Compugen Ltd. Since June 11, 2018. He serves as the Member of Business Advisory Board at Excision BioTherapeutics Inc. since January 2022. Mr. Zweifach also serves as a Operating Advisor at SymBiosis Capital Management LLC. He served as Venture Partner at Medicxi Ventures (UK) LLP since joining it in March 17, 2020. Mr. Zweifach is working with the team of scientific and medical experts. He has experience in life sciences companies. Mr. Zweifach serves as Executive Chairman of Janpix Inc. since December 12, 2019. Mr. Zweifach has experience in senior executive roles in the life sciences industry, with a focus in corporate Partnering, business development, operations, private and public investing and capital raising. Mr. Zweifach served as Chairman of the Board at Palladio Biosciences, Inc. since April 3, 2019 until February 2021 and serves as its Director. He was Independent Non-Executive Director of Realm Therapeutics plc since 2019 until July 31, 2019. Mr. Zweifach is the President of Nuvelution Pharma, Inc. since 2015. He was Chief Executive Officer of Nuvelution Pharma Inc since November 2015 until November 2019. He is a Co-Founder and Senior Advisor at Nuvelution Pharma, Inc. since June 2015. Mr. Zweifach Co-Founded Ascendancy Healthcare, Inc. and served as its Chief Executive Officer from 2010 to 2015. Mr. Zweifach served as Managing Director and Partner at Reedland Capital Partners from 2005 to 2010, where he Headed its life sciences M&A and advisory efforts. Mr. Zweifach joined Reedland in 2005 and Headed life sciences M&A/advisory efforts. Mr. Zweifach is a Senior Executive with extensive experience in the life sciences industry and with an extensive background in corporate Partnering, business development, operations, private and public investing and capital raising. Prior to joining Reedland, he served as Chief Executive Officer and President of Pathways Diagnostics, Inc since 2003 until 2005. He serves as Director at Sydnexis Inc. From 1997 to 2004, he served as Chief Financial Officer and Managing Director of Bay City Capital, where he was responsible for oversight of its finance department and was the President of its M&A division. He served as President of Broker-Dealer Businesses of Bay City Capital LLC. From 1995 to 1997, he served as President and Chief Financial Officer of Epoch Biosciences, which was acquired by Nanogen in 2004. He serves as Chairman of the Board of Lyric Pharmaceuticals Inc. He serves as Chairman of the Board of IMIDomics SL since December 12, 2019. He also sits on the Board of Directors for Syndexis. He serves as Chair of the BAB. He served as Non-Executive Director of Realm Therapeutics Plc. Until July 31, 2019. He is Executive Chair of Kaerus Biosciences, Ltd. He is an Acting President and CBO of IMIDomics, Inc. He served as Independent Director of ESSA Pharma Inc. since July 31, 2019 until October 09, 2025. He served as Independent Non-Executive Director of Realm Therapeutics Plc since December 1, 2017. He serves as Director of Nuvelution Pharma, Inc. He served as a Director of Ascendancy Healthcare, Inc. He served as a Director of Viventia Bio Inc. since February 2015. Mr. Zweifach served as a Director of Anthera Pharmaceuticals, Inc. from March 25, 2013 to April 27, 2016. He served as a Director of ELITechGroup Molecular Diagnostics (Epoch Biosciences, Inc.) since September 1996. He was qualified as a Certified Public Accountant with Coopers & Lybrand. He is a CFA. Mr. Zweifach received his Bachelor of Arts in Biology from UC San Diego and holds an Master of Science in Human Physiology from University of California, Davis.
Positions
- Company NameCompugen Ltd.Stock CodeCGENPositionIndependent DirectorColleagues
- ACAnat Cohen-DayagExecutive Chair
- EOEran OphirCEO, President & Director
- PFPierre FerreChief Operating Officer
- ZLZurit LevineSenior Vice President of Business Development
- MMMichelle MahlerChief Medical Officer
- AMAndrew Mark PardollChairman of Scientific Advisory Board
- GHGilead HalevyIndependent Director
- SSSanford S. ZweifachIndependent Director
- Company NameCarisma Therapeutics, Inc.Stock CodeCARMPositionIndependent Chairman of the Board
